Date receipt dossier
EudraCT number
2016-003312-12
Company / Sponsor
Celyad
Phase
I
Treated organism
Humans
Indication category
Cancer therapy
Disease
cancer
Therapeutic approach
Immunotherapy
Genetic modification
NKG2D-chimeric antigen receptor
Method of transfer of nucleic acid of interest
Moloney Murine Leukemia Virus
Administered biological material
Autologous T-cells retrovirally transduced with a chimeric antigen receptor based on the NKG2D receptor
Route of administration
Intravenous
Locations in Belgium
UZ Gent, Grand Hôpital de Charleroi
Nr of subjects
24 participants
Foreseen duration
4 years
Type of procedure
Contained use only
Current status
Authorized